Lombard Odier Asset Management (Switzerland) Sa Allogene Therapeutics, Inc. Transaction History

Lombard Odier Asset Management (Switzerland) Sa

$1.14 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$10.32 - $17.28 $485,442 - $812,833	-47,039 Reduced 15.41%	258,214 $2.79 Million
Q2 2022 Aug 15, 2022	SELL	$6.78 - $12.28 $1.33 Million - $2.41 Million	-195,966 Reduced 39.1%	305,253 $3.48 Million
Q1 2022 May 16, 2022	SELL	$7.65 - $15.29 $3.79 Million - $7.57 Million	-494,897 Reduced 49.68%	501,219 $4.57 Million
Q4 2021 Feb 14, 2022	BUY	$13.13 - $24.52 $1.07 Million - $2 Million	81,700 Added 8.93%	996,116 $14.9 Million
Q3 2021 Nov 12, 2021	BUY	$21.01 - $27.64 $2.96 Million - $3.89 Million	140,854 Added 18.21%	914,416 $23.5 Million
Q2 2021 Aug 13, 2021	BUY	$23.49 - $35.8 $5.56 Million - $8.48 Million	236,824 Added 44.12%	773,562 $20.2 Million
Q1 2021 May 17, 2021	BUY	$25.79 - $39.02 $13.8 Million - $20.9 Million	536,738 New	536,738 $18.9 Million

Others Institutions Holding ALLO

# of Institutions

163

Shares Held

134M

Call Options Held

59.4K

Put Options Held

113K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $262M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lombard Odier Asset Management (Switzerland) Sa, based on Form 13F filings with the SEC.

News

Stay updated on Lombard Odier Asset Management (Switzerland) Sa with notifications on news.

Account